Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

Summary

The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.

Timeline

Start

2022-12-19

Primary completion

2024-03-26

Completion

2024-04-30

Outcome

Met primary endpoint

release “positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata” equilliumbio.com ↗

Drugs

Indications